Hadassah

Collaboration Announced to Develop Hadassah Drug to Treat “Untreatable” NASH Liver Disease

Friday, Aug 5 2016

Hadasit, the Hadassah Medical Organization’s technology transfer company, has signed an agreement with BioLineRx Ltd. to develop a drug to treat non-alcoholic steatohepatitis (NASH), based on the pre-clinical work of Hadassah’s Prof. Rifaat Safadi, head of its Liver Unit. Currently, there are no Federal Drug Administration-approved treatments for NASH.

NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD) and, in many cases, leads to cirrhosis of the liver and, ultimately, liver cancer. This “in-licensing agreement” represents a partnership between two companies with shared intentions, goals, and fields of interest. "Under the collaboration,” explains Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx,” Novartis will provide us with valuable professional advice and consultancy throughout the development process. This project fits our strategic focus on the immunology space, since it works through modulation of the immune system.”

The drug candidate, to be called BL-1210, offers a novel mechanism for controlling liver fibrosis, the scarring process that represents the liver's response to injury. When scar tissue builds up and takes over most of the liver, cirrhosis is the result. By modulating the immune system, the drug would reduce scarring and control the disease’s progression.

As Hadasit explains about the Hadassah Medical Center on its website, “The combination of practical experience, the ability to pinpoint medical needs, and cutting-edge research has yielded a huge potential for ideas, innovation, and developments in all aspects of medicine, including therapeutics, diagnostics, and medical devices. Founded in 1986, Hadasit has been investing in turning ideas into viable products and services for the benefit of humanity.”

Comments

From: Michelle on August 25, 2016
I was first diagnosed with NASH in 2003. Nobody I knew had ever heard of NASH. At the beginning even some of my doctors, often were unknowldgeable on NASH. I was their key to unlock the information vault. I am willing to be a test subject.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, May 23 2017

First Ladies Melania Trump and Sara Netanyahu Visit Hadassah Hospital

Please share our pride in Hadassah Hospital, singled out by the Israeli government to showcase the nation’s top-quality medicine, top doctors, and innovative medical research. First Lady Melania Trump and First Lady Sara Netanyahu visited Hadassah Hospital Ein Kerem on May 22...

READ MORE ›
alt_text

Wednesday, May 10 2017

Hadassah’s Melanoma Maven Featured in Hadassah Magazine

Metastatic melanoma is typically fatal, but Hadassah Hospital’s Prof. Michal Lotem, a world-renowned, cutting-edge physician/scientist, is trailblazing new treatments that are being watched around the globe.

READ MORE ›
alt_text

Monday, May 1 2017

Hadassah Surgeon to Light Torch at Jerusalem Independence Day Ceremony

Meet Prof. Ahmed Eid of Hadassah Hospital, who will light the torch at Jerusalem's Independence Day Ceremony, in honor of the city’s doctors who tirelessly work to save lives and improve the quality of life of men, women and children.

READ MORE ›

Friday, Apr 28 2017

Surgeons Perform World’s First-Ever Dual Robotic Surgery
 at Jerusalem’s Hadassah Hospital

The world’s first-of-its-kind dual robotic surgery was performed on April 23 at Hadassah Hospital Ein Kerem in Jerusalem, announced National President Ellen Hershkin of Hadassah, the Women’s Zionist Organization of America, Inc. (HWZOA).

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More